The future of pediatric oncology: Comprehensive review of causes, mortality, and treatment strategies
Main Article Content
Keywords
Pediatric oncology, Mortality ratio, Chemotherapy, Immunotherapy, Future strategies , Challenges
Abstract
Pediatric oncology is confronting rising cancer rates among children, which poses a significant global health challenge. This review article delves into the multifaceted aspects of pediatric cancers, including their etiology, advanced diagnostic methods, and comprehensive treatment approaches. The article explores both genetic predispositions and environmental factors that contribute to the development of cancer in children. It underscores the importance of cutting-edge diagnostic tools such as next-generation sequencing and liquid biopsies. These technologies have revolutionized our understanding of cancer’s molecular basis, leading to more precise diagnoses and enabling personalized treatment regimens. In terms of treatment, the review discusses traditional methods like chemotherapy, radiation therapy, immunotherapy, target therapy, stem cell transplant and surgical interventions. It also sheds light on innovative therapies such as immunotherapy and targeted treatments that have shown promise in improving survival rates while minimizing adverse effects. The review also addresses the stark disparities in healthcare access and survival rates between developed and developing countries. It emphasizes the critical need for global efforts to provide equitable care to all pediatric cancer patients. Looking ahead, the article highlights the potential of personalized medicine to transform pediatric oncology. It also points to emerging therapies and international collaborations as key factors in advancing care and outcomes for young patients with cancer. This comprehensive review serves as a valuable resource for healthcare professionals, researchers, and policymakers. It provides a thorough analysis of current challenges in pediatric oncology and offers a forward-looking perspective on opportunities for future advancements.
References
1. Cohen-Gogo S, Denburg A, Villani A, Thacker N, Egan G, Rafael M, et al. Precision oncology for children: a primer for paediatricians. Paediatr Child Health. 2023;28(5):278-84.
2. Ostrom QT, de Blank P, Kruchko C, Petersen CM, Liao P, Finlay JL, et al. Alex’s Lemonade Stand Foundation infant and childhood primary brain and central nervous system tumors diagnosed in the United States in 2007–2011. Neuro Oncol. 2014;16(Suppl 10):x1-36.
3. van Heerden J, Hendricks M, Poole J, Büchner A, Naidu G, du Plessis J, et al. The implementation of a national paediatric oncology protocol for neuroblastoma in South Africa. Cancer Causes Control. 2021;32(7):725-37.
4. Egan G, Tasian SK. Relapsed pediatric acute myeloid leukaemia: state-of-the-art in 2023. Haematologica. 2023;108(8):1963-77.
5. Hamid NF, Albalawi FM, Aloufi AA, Hamas RA, Alanazi NAH, Alanazi TH. Epidemiological trends in childhood cancer in Saudi Arabia. Clin Cancer Investig J. 2022;11(5):42-8.
6. Johann P. Invited review: dysregulation of chromatin remodellers in paediatric brain tumours – SMARCB1 and beyond. Neuropathol Appl Neurobiol. 2020;46(1):57-72.
7. Xu J, Margol A, Asgharzadeh S, Erdreich-Epstein A. Pediatric brain tumor cell lines. J Cell Biochem. 2014;116(2):218-24.
8. Basheer F, Dhar P, Samarasinghe RM. Zebrafish models of paediatric brain tumours. Int J Mol Sci. 2022;23(17):9920.
9. Coughtrey A, Millington A, Bennett S, Christie D, Hough R, Su M, et al. The effectiveness of psychosocial interventions for psychological outcomes in pediatric oncology: a systematic review. J Pain Symptom Manage. 2018;55(3):1004-17.
10. Guimarães TM, da Silva LF, Santo FH, de Moraes JR, Pacheco ST. Cuidado paliativo em oncologia pediátrica na formação do enfermeiro. Rev Gaúcha Enferm. 2017;38(1):e65876.
11. Hua CH, Mascia A, Seravalli E, Lomax A, Seiersen K, Ulin K, et al. Advances in radiotherapy technology for pediatric cancer patients and roles of medical physicists: COG and SIOP Europe perspectives. Pediatr Blood Cancer. 2021;68(S2):e28985.
12. Boterberg T, Dunlea C, Harrabi S, Janssens GO, Laprie A, Whitfield GA, et al. Contemporary paediatric radiation oncology. Arch Dis Child. 2022;108(5):332-7.
13. Rao P, Furst L, Meyran D, Mayoh C, Neeson PJ, Terry R, et al. Advances in CAR T cell immunotherapy for paediatric brain tumours. Front Oncol. 2022;12:873836.
14. Ferreras C, Fernández L, Clares-Villa L, Ibáñez-Navarro M, Martín-Cortázar C, Esteban-Rodríguez I, et al. Facing CAR T cell challenges on the deadliest paediatric brain tumours. Cells. 2021;10(11):2940.
15. Chambers G, Frood R, Patel C, Scarsbrook A. 18F-FDG PET-CT in paediatric oncology: established and emerging applications. Br J Radiol. 2019;92(1094):20180584.
16. Falzon S, Galea N, Calvagna V, Pham JT, Grech L, Azzopardi LM. Development and use of an innovative gap finding tool to create a pharmaceutical care model within a paediatric oncology setting. J Oncol Pharm Pract. 2021;29(1):74-82.
17. Graetz DE, Agulnik A, Ranadive R, Vedaraju Y, Chen YC, Chantada G, et al. Global effect of the COVID-19 pandemic on paediatric cancer care: a cross-sectional study. Lancet Child Adolesc Health. 2021;5(5):332-40.
18. Spector LG, Pankratz N, Marcotte EL. Genetic and nongenetic risk factors for childhood cancer. Pediatr Clin North Am. 2015;62(1):11-25.
19. Priestley P, Baber J, Lolkema MP, Steeghs N, de Bruijn E, Shale C, et al. Pan-cancer whole-genome analyses of metastatic solid tumours. Nature. 2019;575(7781):210-6.
20. Ma X, Liu Y, Alexandrov LB, Edmonson MN, Gawad C, Zhou X, et al. Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours. Nature. 2018;555(7696):371-6.
21. Sweet-Cordero EA, Biegel JA. The genomic landscape of pediatric cancers: implications for diagnosis and treatment. Science. 2019;363(6432):1170-5.
22. Capasso M, Montella A, Tirelli M, Maiorino T, Cantalupo S, Iolascon A. Genetic predisposition to solid pediatric cancers. Front Oncol. 2020;10:590033.
23. Kuhlen M, Taeubner J, Brozou T, Wieczorek D, Siebert R. Family-based germline sequencing in children with cancer. Oncogene. 2018;38(9):1367-80.
24. Kamihara J, Bourdeaut F, Foulkes WD, Molenaar JJ, Mossé YP, Nakagawara A, et al. Retinoblastoma and neuroblastoma predisposition and surveillance. Clin Cancer Res. 2017;23(13):e98-e106.
25. Knoll J, Li A, Smith CH, Schratz KE, Cooper S, Meah T, et al. Improving detection of cancer predisposition syndromes in pediatric oncology. J Pediatr Hematol Oncol. 2020;43(6):e891-e896.
26. Linga BG, Mohammed SGAA, Farrell T, Rifai HA, Al-Dewik N, Qoronfleh MW. Genomic newborn screening for pediatric cancer predisposition syndromes: a holistic approach. Cancers. 2024;16(11):2017.
27. Waszak SM, Robinson G, Gudenas B, Smith K, Forget A, Kojic M, et al. Germline elongator mutations in Sonic Hedgehog medulloblastoma. Nature. 2020;580(7803):396-401.
28. D’Aquila KR, Kessler E, Cooper KL, Durst AL, Meade J. Assessment of factors associated with the evaluation of children for leukemia predisposition syndromes: a retrospective single-center study. J Pediatr Hematol Oncol. 2023;45(5):e597-e602.
29. Reschke M, Biewald E, Bronstein L, Brecht IB, Dittner-Moormann S, Driever F, et al. Eye tumors in childhood as first sign of tumor predisposition syndromes: insights from an observational study conducted in Germany and Austria. Cancers. 2021;13(8):1876.
30. Rodríguez-Galindo C, Friedrich P, Alcasabas P, Antillón F, Banavali S, Castillo L, et al. Toward the cure of all children with cancer through collaborative efforts: pediatric oncology as a global challenge. J Clin Oncol. 2015;33(27):3065-73.
31. Grabas MR, Kjær SK, Frederiksen K, Winther JF, Erdmann F, Dehlendorff C, et al. Incidence and time trends of childhood cancer in Denmark, 1943–2014. Acta Oncol. 2020;59(5):588-95.
32. Rossi F, Ricci F, Botti S, Bertin D, Breggiè S, Casalaz R, et al. The Italian consensus conference on the role of rehabilitation for children and adolescents with leukemia, central nervous system, and bone tumors. Pediatr Blood Cancer. 2020;67(12):e28719.
33. Pedretti L, Massa S, Leardini D, Muratore E, Rahman S, Pession A, et al. Role of nutrition in pediatric patients with cancer. Nutrients. 2023;15(3):710.
34. Mirutse MK, Palm MT, Tolla MT, Memirie ST, Kefyalew ES, Hailu D, et al. Cost of childhood cancer treatment in Ethiopia. PLoS One. 2023;18(6):e0286461.
35. Sandeberg MA, Olsson M, Ek T, Enskär K, Stenmarker M, Pergert P. Nurses’ perceptions of the impact of a national educational program in pediatric oncology nursing: a cross-sectional evaluation. J Pediatr Hematol Oncol Nurs. 2023;40(3):178-84.
36. Schwartz KM, Honstain C, Spruit JL, Harris M. Allogeneic hematopoietic stem cell transplant for acute lymphoblastic leukemia in a pediatric patient after COVID-19 infection complicated by MIS-C. J Pediatr Health Care. 2022;36(3):280-5.
37. Baroni L, Bouffet É. The impact of the COVID-19 pandemic in pediatric oncology units: a lesson of resilience and hope. Cancer. 2022;128(7):1363-4.
38. Conyers R, Devaraja S, Elliott DA. Systematic review of pharmacogenomics and adverse drug reactions in paediatric oncology patients. Pediatr Blood Cancer. 2017;65(4):e26887.
39. Bo L, Wang Y, Li Y, Wurpel JND, Huang Z, Chen ZS. The battlefield of chemotherapy in pediatric cancers. Cancers. 2023;15(7):1963.
40. Lindsey ML, Lange RA, Parsons H, Andrews TC, Aune GJ. The tell-tale heart: molecular and cellular responses to childhood anthracycline exposure. AJP Heart Circ Physiol. 2014;307(10):H1379-H1389.
41. McNerney ME, Godley LA, Le Beau MM. Therapy-related myeloid neoplasms: when genetics and environment collide. Nat Rev Cancer. 2017;17(9):513-27.
42. Ikonomidou C. Chemotherapy and the pediatric brain. Mol Cell Pediatr. 2018;5(1):8.
43. Advani PG, Schonfeld SJ, Curtis RE, Dores GM, Linet MS, Sigel B, et al. Risk of therapy-related myelodysplastic syndrome/acute myeloid leukemia after childhood cancer: a population-based study. Leukemia. 2019;33(12):2947-78.
44. Vázquez-López R, Rojas OR, Moreno AI, Favila JEU, Barreto AP, G O, et al. Antibiotic-resistant septicemia in pediatric oncology patients associated with post-therapeutic neutropenic fever. Antibiotics. 2019;8(3):106.
45. de Lacerda AF, Martínez MA, Dumont B, Leiss U, Kokkinou G, Scheinemann K, et al. Embracing paediatric palliative care in paediatric oncology from diagnosis onwards. Pediatr Blood Cancer. 2023;70(10):e30593.
46. Soeteman M, Kappen TH, van Engelen M, Marcelis M, Kilsdonk E, van den Heuvel-Eibrink MM, et al. Validation of a modified bedside pediatric early warning system score for detection of clinical deterioration in hospitalized pediatric oncology patients: a prospective cohort study. Pediatr Blood Cancer. 2022;70(1):e29472.
47. Reschke A, Richards RM, Smith SM, Long AH, Marks LJ, Schultz L, et al. Development of clinical pathways to improve multidisciplinary care of high-risk pediatric oncology patients. Front Oncol. 2022;12:835742.
48. Bhosale SJ, Joshi M, Patil V, Kothekar AT, Myatra SN, Divatia JV, et al. Epidemiology and predictors of hospital outcomes of critically ill pediatric oncology patients: a retrospective study. Indian J Crit Care Med. 2022;25(10):1183-8.
49. Murphy Salem SL, Perez JM, Staffa SJ, Duncan CN, Graham RJ. Outcomes for pediatric oncology and hematopoietic stem cell transplantation patients who undergo tracheostomy placement: a Pediatric Health Information System database cohort study, 2009–2020. Pediatr Crit Care Med. 2024;25(6):e283-e290.
50. Llanos-Paez C, Staatz CE, Lawson R, Hennig S. A population pharmacokinetic model of gentamicin in pediatric oncology patients to facilitate personalized dosing. Antimicrob Agents Chemother. 2017;61(8):e00206-17.
51. Wraight TI, Namachivayam SP, Maiden MJ, Erickson S, Oberender F, Singh P, et al. Trends in childhood oncology admissions to ICUs in Australia and New Zealand. Pediatr Crit Care Med. 2023;24(10):e487-e497.
52. Ward E, DeSantis C, Robbins A, Kohler B, Jemal A. Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin. 2014;64(2):83-103.
53. Fujibuchi T, Matsubara K, Hamada N. NCRP statement No. 13 “NCRP recommendations for ending routine gonadal shielding during abdominal and pelvic radiography” and its accompanying documents. Underpinnings and recent developments. Hoken Butsuri. 2021;56(3):107-15.
54. Davis JT, Kwatra N, Schooler GR. Pediatric whole-body MRI: a review of current imaging techniques and clinical applications. J Magn Reson Imaging. 2014.
55. Davis JT, Kwatra N, Schooler GR. Pediatric whole-body MRI: a review of current imaging techniques and clinical applications. J Magn Reson Imaging. 2014;40(4):783-99.
56. Brenner DJ, Hall EJ. Computed tomography—an increasing source of radiation exposure. N Engl J Med. 2007;357(22):2277-84.
57. Pearce MS, Salotti JA, Little MP, McHugh K, Lee C, Kim KP, et al. Radiation exposure from CT scans in childhood and subsequent risk of leukaemia and brain tumours: a retrospective cohort study. Lancet. 2012;380(9840):499-505.
58. Frush DP, Applegate KE, Yan X, et al. Radiation exposure and dose reduction in pediatric imaging. Pediatr Radiol. 2003;33(4):226-34.
59. Strauss KJ, Goske MJ, Kaste SC, et al. Image gently: ten steps you can take to optimize image quality and lower CT dose for pediatric patients. AJR Am J Roentgenol. 2010;194(4):868-73.
60. Mettler FA Jr, Bhargavan M, Faulkner K, et al. Radiologic and nuclear medicine studies in the United States and worldwide: frequency, radiation dose, and comparison with other radiation sources—1950–2007. Radiology. 2009;253(2):520-31.
61. Thomsen HS. Contrast media safety—an update. Eur J Radiol. 2011;80(1):77-82.
62. Rabiner JE, Friedman LM, Khine H, Avner JR, Tsung JW. Accuracy of point-of-care ultrasound for diagnosis of skull fractures in children. Pediatrics. 2013;131(6):e1757-64.
63. Ferre RM, Sweeney K, Kahn J, et al. Ultrasound-guided lumbar puncture in pediatric oncology patients. Pediatr Emerg Care. 2017;33(2):96-100.
64. Sidhu PS, Cantisani V, Dietrich CF, et al. The evolving role of contrast-enhanced ultrasound in pediatric oncology. Ultraschall Med. 2018;39(6):602-15.
65. Prada F, Del Bene M, Fornaro R, et al. Intraoperative ultrasound in pediatric brain tumor surgery. Childs Nerv Syst. 2016;32(10):1911-20.
66. Brenner DJ, Elliston CD, Hall EJ, Berdon WE. Estimated risks of radiation-induced fatal cancer from pediatric CT. AJR Am J Roentgenol. 2001;176(2):289-96.
67. Slovis TL. Children, computed tomography radiation dose, and the as low as reasonably achievable (ALARA) concept. Pediatrics. 2003;112(4):971-2.
68. Kalra MK, Maher MM, Toth TL, et al. Strategies for CT radiation dose optimization. Radiology. 2004;230(3):619-28.
69. McCollough CH, Schueler BA. Calculation of effective dose. Med Phys. 2000;27(5):828-37.
70. Brenner DJ. Slowing the increase in the population dose resulting from CT scans. Radiat Res. 2010;174(6):809-15.
71. Dillman JR, Ellis JH, Cohan RH, Strouse PJ, Jan SC. Allergic-like breakthrough reactions to gadolinium contrast agents after corticosteroid and antihistamine premedication. AJR Am J Roentgenol. 2008;190(1):187-90.
72. Patel RA, Yee J. Pediatric contrast-induced nephropathy: what is the risk? Pediatr Radiol. 2013;43(1):1-7.
73. Clement O, Dewachter P, Mouton-Faivre C, et al. Immediate hypersensitivity to contrast agents: the French 5-year CIRTACI study. EClinicalMedicine. 2018;1:51-61.
74. Willemink MJ, Persson M, Pourmorteza A, et al. Photon-counting CT: technical principles and clinical prospects. Radiology. 2018;289(2):293-312.
75. Poretti A, Meoded A, Huisman TAGM. Neuroimaging of pediatric brain tumors: update on recent advances. Curr Opin Pediatr. 2012;24(6):697-703.
76. Messiou C, Orton M, Ang JE, et al. Advanced MRI for the assessment of treatment response in oncology. Br J Radiol. 2016;89(1062):20150314.
77. Chawla S, Wang S, Wolf RL, et al. Diffusion-weighted imaging in pediatric brain tumors. J Neurooncol. 2013;114(2):193-200.
78. Mafee MF, Goodwin J, Dorodi S. Orbital tumors and tumor-like lesions: role of CT and MRI. Radiol Clin North Am. 1999;37(1):169-83.
79. Hicks RJ, Lau EWF, Drummond E, et al. Role of PET in pediatric oncology. J Nucl Med. 2011;52(5):730-43.
80. Jadvar H. Targeted radionuclide therapy: an evolution toward precision oncology. AJR Am J Roentgenol. 2017;209(2):277-88.
81. Pirotte BJ, Lubansu A, Massager N, et al. Clinical impact of integrating positron emission tomography during surgery in pediatric brain tumors. J Neurosurg. 2010;113(3):533-43.
82. Dilsizian V, Bacharach SL, Beanlands RS, et al. PET myocardial perfusion and metabolism clinical imaging. J Nucl Cardiol. 2009;16(4):651.
83. Esposito C, Escolino M, Turrà F, et al. Robot-assisted surgery in pediatric oncology. World J Surg. 2017;41(4):835-42.
84. Warmann SW, Schaefer JF, Fuchs J. MRI-based 3D visualization in pediatric renal tumors. Eur J Pediatr Surg. 2014;24(3):212-8.
85. Abdelhafeez AH, Refaat M, Elsharkawy A. Fluorescence-guided surgery in pediatric oncology. J Pediatr Surg. 2018;53(11):2190-6.
86. Marescaux J, Diana M. Next step in minimally invasive surgery: computer-assisted surgery. Br J Surg. 2015;102(6):e90-9.
87. Sala F, Bricolo A, Talacchi A, et al. Intraoperative MRI in pediatric neurosurgery. Childs Nerv Syst. 2006;22(5):458-65.
88. Rothenberg SS. Thoracoscopic surgery in infants and children. Surg Endosc. 2008;22(2):329-35.
89. Parikh DH, Rasiah SV. Thoracoscopic surgery in pediatric oncology. Semin Pediatr Surg. 2007;16(4):256-62.
90. Stiller CA, Parkin DM. International variations in the incidence of childhood soft-tissue sarcomas. Paediatr Perinat Epidemiol. 1994;8(1):107-19.
91. Dupuis LL, Sung L, Molassiotis A, et al. 2016 updated MASCC/ESMO consensus recommendations. Support Care Cancer. 2017;25(1):333-40.
92. Sonis ST. Pathobiology of oral mucositis. J Support Oncol. 2004;2(1):21-32.
93. Stringer AM, Gibson RJ, Logan RM, et al. Chemotherapy-induced mucositis: the role of the gastrointestinal microbiome. Cancer Treat Rev. 2009;35(8):697-706.
94. Cheng KKF, Lee V, Li CH, et al. Incidence and risk factors of oral mucositis in pediatric oncology patients. Support Care Cancer. 2011;19(5):751-9.
95. Elting LS, Keefe DM, Sonis ST, et al. Burden of illness of chemotherapy-induced oral mucositis. Cancer. 2008;113(10):2704-13.
96. Gupta S, Howard SC, Hunger SP, et al. Treating childhood cancer in low- and middle-income countries. Nat Rev Cancer. 2015;15(11):673-82.
97. Landier W, Bhatia S, Eshelman DA, et al. Adherence to chemotherapy administration guidelines. J Clin Oncol. 2004;22(21):4359-67.
98. Rinke ML, Bundy DG, Shore AD, et al. Pediatric chemotherapy safety and quality improvement. Pediatrics. 2012;130(6):e1464-70.
99. Delaney G, Jacob S, Featherstone C, Barton M. The role of radiotherapy in cancer treatment. Cancer. 2005;104(6):1129-37.
100. Merchant TE, Pollack IF, Loeffler JS. Brain tumors across the age spectrum. J Clin Oncol. 2010;28(32):4787-96.
101. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354(2):166-78.
102. Yock TI, Tarbell NJ. Technology insight: proton beam radiotherapy. Nat Clin Pract Oncol. 2004;1(2):97-103.
103. Eaton BR, Yock T, Merchant TE. Advances in radiotherapy for pediatric cancer. Lancet Oncol. 2015;16(19):e460-70.
104. Duffton A, McNee SG, Coles CE, et al. Pediatric radiotherapy facilities and emergency preparedness. Clin Oncol. 2012;24(4):e57-64.
105. Lutz S, Chow E, Hoskin P, et al. Palliative radiotherapy. Radiother Oncol. 2014;110(3):479-85.
106. Constine LS, Ronckers CM, Hua CH, et al. Pediatric radiation oncology training. Int J Radiat Oncol Biol Phys. 2008;72(3):695-700.
107. Atun R, Jaffray DA, Barton MB, et al. Expanding global access to radiotherapy. Lancet Oncol. 2015;16(10):1153-86.
108. Mody R, Prensner JR, Everett J, et al. Precision medicine in pediatric oncology. Cancer Discov. 2017;7(5):446-59.
109. Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015;372(9):793-5.
110. Parsons DW, Roy A, Yang Y, et al. Diagnostic yield of clinical tumor and germline whole-exome sequencing. JAMA Oncol. 2016;2(5):616-24.
111. Mossé YP, Laetsch TW, Nagasubramanian R, et al. Efficacy of larotrectinib in TRK fusion–positive cancers. N Engl J Med. 2018;378(8):731-9.
112. Pearson ADJ, Pfister SM, Baruchel A, et al. From biology to clinical trials. Lancet Oncol. 2016;17(10):e415-25.
113. Allen CE, Laetsch TW, Mody R, et al. Targeted therapy in pediatric oncology. Nat Rev Clin Oncol. 2017;14(5):277-88.
114. Hargrave DR, Bouffet E, Tabori U, et al. Pediatric brain tumors. Nat Rev Dis Primers. 2019;5(1):1-25.
115. Vassal G, Kearns P, Blanc P, et al. New drugs for children and adolescents with cancer. Lancet Oncol. 2013;14(2):e60-9.
116. Yu AL, Gilman AL, Ozkaynak MF, et al. Anti-GD2 antibody with GM-CSF and interleukin-2. N Engl J Med. 2010;363(14):1324-34.
117. Cheung NK, Dyer MA. Neuroblastoma. N Engl J Med. 2013;369(21):2021-30.
118. Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults. N Engl J Med. 2018;378(5):439-48.
119. Mackall CL, Rhee EH, Read EJ, et al. A pilot study of consolidative immunotherapy. Clin Cancer Res. 2008;14(15):4850-8.
120. Majzner RG, Mackall CL. CAR T cell therapy in solid tumors. Cancer Discov. 2018;8(10):1219-26.
121. Lehrnbecher T, Robinson P, Fisher B, et al. Guideline for fever and neutropenia. J Clin Oncol. 2012;30(35):4427-38.
122. Lehrnbecher T, Cornely OA, Bow EJ, et al. Isavuconazole for pediatric patients. Clin Infect Dis. 2016;63(11):1529-36.
123. Fisher BT, Zaoutis TE, Dvorak CC, et al. Pediatric invasive fungal infection risk score. Clin Infect Dis. 2014;59(9):1224-31.
124. Gerding DN, Johnson S, Rupnik M, et al. Clostridioides difficile infection. Clin Infect Dis. 2014;59(2):e1-38.
125. Pieters R, Schrappe M, De Lorenzo P, et al. A treatment protocol for infants with ALL. Blood. 2007;109(3):926-35.
126. Alexander S, Fisher BT, Gaur AH, et al. Effect of levofloxacin prophylaxis. JAMA. 2018;320(10):995-1004.
127. Oeffinger KC, Hudson MM. Long-term complications following childhood cancer. Annu Rev Med. 2004;55:349-67.
128. Lipshultz SE, Franco VI, Miller TL, et al. Cardiovascular disease in adult survivors of childhood cancer. Annu Rev Med. 2015;66:161-76.
129. Travis LB, Hill DA, Dores GM, et al. Breast cancer following radiotherapy. J Natl Cancer Inst. 2005;97(19):1428-37.
130. Gurney JG, Ness KK, Sibley SD, et al. Metabolic syndrome and cardiovascular risk. J Clin Oncol. 2006;24(31):4799-806.
131. Armstrong GT, Oeffinger KC, Chen Y, et al. Modifiable risk factors and major cardiac events. J Clin Oncol. 2013;31(29):3673-80.
132. Pritchard-Jones K, Dixon-Woods M, Naafs-Wilstra M, et al. Improving access to clinical trials for children. Lancet. 2011;378(9801):1593-601.
133. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-74.
134. Vassal G, Fitzgerald E, Schrappe M, et al. Challenges for drug development for children. Nat Rev Clin Oncol. 2013;10(12):712-23.
2. Ostrom QT, de Blank P, Kruchko C, Petersen CM, Liao P, Finlay JL, et al. Alex’s Lemonade Stand Foundation infant and childhood primary brain and central nervous system tumors diagnosed in the United States in 2007–2011. Neuro Oncol. 2014;16(Suppl 10):x1-36.
3. van Heerden J, Hendricks M, Poole J, Büchner A, Naidu G, du Plessis J, et al. The implementation of a national paediatric oncology protocol for neuroblastoma in South Africa. Cancer Causes Control. 2021;32(7):725-37.
4. Egan G, Tasian SK. Relapsed pediatric acute myeloid leukaemia: state-of-the-art in 2023. Haematologica. 2023;108(8):1963-77.
5. Hamid NF, Albalawi FM, Aloufi AA, Hamas RA, Alanazi NAH, Alanazi TH. Epidemiological trends in childhood cancer in Saudi Arabia. Clin Cancer Investig J. 2022;11(5):42-8.
6. Johann P. Invited review: dysregulation of chromatin remodellers in paediatric brain tumours – SMARCB1 and beyond. Neuropathol Appl Neurobiol. 2020;46(1):57-72.
7. Xu J, Margol A, Asgharzadeh S, Erdreich-Epstein A. Pediatric brain tumor cell lines. J Cell Biochem. 2014;116(2):218-24.
8. Basheer F, Dhar P, Samarasinghe RM. Zebrafish models of paediatric brain tumours. Int J Mol Sci. 2022;23(17):9920.
9. Coughtrey A, Millington A, Bennett S, Christie D, Hough R, Su M, et al. The effectiveness of psychosocial interventions for psychological outcomes in pediatric oncology: a systematic review. J Pain Symptom Manage. 2018;55(3):1004-17.
10. Guimarães TM, da Silva LF, Santo FH, de Moraes JR, Pacheco ST. Cuidado paliativo em oncologia pediátrica na formação do enfermeiro. Rev Gaúcha Enferm. 2017;38(1):e65876.
11. Hua CH, Mascia A, Seravalli E, Lomax A, Seiersen K, Ulin K, et al. Advances in radiotherapy technology for pediatric cancer patients and roles of medical physicists: COG and SIOP Europe perspectives. Pediatr Blood Cancer. 2021;68(S2):e28985.
12. Boterberg T, Dunlea C, Harrabi S, Janssens GO, Laprie A, Whitfield GA, et al. Contemporary paediatric radiation oncology. Arch Dis Child. 2022;108(5):332-7.
13. Rao P, Furst L, Meyran D, Mayoh C, Neeson PJ, Terry R, et al. Advances in CAR T cell immunotherapy for paediatric brain tumours. Front Oncol. 2022;12:873836.
14. Ferreras C, Fernández L, Clares-Villa L, Ibáñez-Navarro M, Martín-Cortázar C, Esteban-Rodríguez I, et al. Facing CAR T cell challenges on the deadliest paediatric brain tumours. Cells. 2021;10(11):2940.
15. Chambers G, Frood R, Patel C, Scarsbrook A. 18F-FDG PET-CT in paediatric oncology: established and emerging applications. Br J Radiol. 2019;92(1094):20180584.
16. Falzon S, Galea N, Calvagna V, Pham JT, Grech L, Azzopardi LM. Development and use of an innovative gap finding tool to create a pharmaceutical care model within a paediatric oncology setting. J Oncol Pharm Pract. 2021;29(1):74-82.
17. Graetz DE, Agulnik A, Ranadive R, Vedaraju Y, Chen YC, Chantada G, et al. Global effect of the COVID-19 pandemic on paediatric cancer care: a cross-sectional study. Lancet Child Adolesc Health. 2021;5(5):332-40.
18. Spector LG, Pankratz N, Marcotte EL. Genetic and nongenetic risk factors for childhood cancer. Pediatr Clin North Am. 2015;62(1):11-25.
19. Priestley P, Baber J, Lolkema MP, Steeghs N, de Bruijn E, Shale C, et al. Pan-cancer whole-genome analyses of metastatic solid tumours. Nature. 2019;575(7781):210-6.
20. Ma X, Liu Y, Alexandrov LB, Edmonson MN, Gawad C, Zhou X, et al. Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours. Nature. 2018;555(7696):371-6.
21. Sweet-Cordero EA, Biegel JA. The genomic landscape of pediatric cancers: implications for diagnosis and treatment. Science. 2019;363(6432):1170-5.
22. Capasso M, Montella A, Tirelli M, Maiorino T, Cantalupo S, Iolascon A. Genetic predisposition to solid pediatric cancers. Front Oncol. 2020;10:590033.
23. Kuhlen M, Taeubner J, Brozou T, Wieczorek D, Siebert R. Family-based germline sequencing in children with cancer. Oncogene. 2018;38(9):1367-80.
24. Kamihara J, Bourdeaut F, Foulkes WD, Molenaar JJ, Mossé YP, Nakagawara A, et al. Retinoblastoma and neuroblastoma predisposition and surveillance. Clin Cancer Res. 2017;23(13):e98-e106.
25. Knoll J, Li A, Smith CH, Schratz KE, Cooper S, Meah T, et al. Improving detection of cancer predisposition syndromes in pediatric oncology. J Pediatr Hematol Oncol. 2020;43(6):e891-e896.
26. Linga BG, Mohammed SGAA, Farrell T, Rifai HA, Al-Dewik N, Qoronfleh MW. Genomic newborn screening for pediatric cancer predisposition syndromes: a holistic approach. Cancers. 2024;16(11):2017.
27. Waszak SM, Robinson G, Gudenas B, Smith K, Forget A, Kojic M, et al. Germline elongator mutations in Sonic Hedgehog medulloblastoma. Nature. 2020;580(7803):396-401.
28. D’Aquila KR, Kessler E, Cooper KL, Durst AL, Meade J. Assessment of factors associated with the evaluation of children for leukemia predisposition syndromes: a retrospective single-center study. J Pediatr Hematol Oncol. 2023;45(5):e597-e602.
29. Reschke M, Biewald E, Bronstein L, Brecht IB, Dittner-Moormann S, Driever F, et al. Eye tumors in childhood as first sign of tumor predisposition syndromes: insights from an observational study conducted in Germany and Austria. Cancers. 2021;13(8):1876.
30. Rodríguez-Galindo C, Friedrich P, Alcasabas P, Antillón F, Banavali S, Castillo L, et al. Toward the cure of all children with cancer through collaborative efforts: pediatric oncology as a global challenge. J Clin Oncol. 2015;33(27):3065-73.
31. Grabas MR, Kjær SK, Frederiksen K, Winther JF, Erdmann F, Dehlendorff C, et al. Incidence and time trends of childhood cancer in Denmark, 1943–2014. Acta Oncol. 2020;59(5):588-95.
32. Rossi F, Ricci F, Botti S, Bertin D, Breggiè S, Casalaz R, et al. The Italian consensus conference on the role of rehabilitation for children and adolescents with leukemia, central nervous system, and bone tumors. Pediatr Blood Cancer. 2020;67(12):e28719.
33. Pedretti L, Massa S, Leardini D, Muratore E, Rahman S, Pession A, et al. Role of nutrition in pediatric patients with cancer. Nutrients. 2023;15(3):710.
34. Mirutse MK, Palm MT, Tolla MT, Memirie ST, Kefyalew ES, Hailu D, et al. Cost of childhood cancer treatment in Ethiopia. PLoS One. 2023;18(6):e0286461.
35. Sandeberg MA, Olsson M, Ek T, Enskär K, Stenmarker M, Pergert P. Nurses’ perceptions of the impact of a national educational program in pediatric oncology nursing: a cross-sectional evaluation. J Pediatr Hematol Oncol Nurs. 2023;40(3):178-84.
36. Schwartz KM, Honstain C, Spruit JL, Harris M. Allogeneic hematopoietic stem cell transplant for acute lymphoblastic leukemia in a pediatric patient after COVID-19 infection complicated by MIS-C. J Pediatr Health Care. 2022;36(3):280-5.
37. Baroni L, Bouffet É. The impact of the COVID-19 pandemic in pediatric oncology units: a lesson of resilience and hope. Cancer. 2022;128(7):1363-4.
38. Conyers R, Devaraja S, Elliott DA. Systematic review of pharmacogenomics and adverse drug reactions in paediatric oncology patients. Pediatr Blood Cancer. 2017;65(4):e26887.
39. Bo L, Wang Y, Li Y, Wurpel JND, Huang Z, Chen ZS. The battlefield of chemotherapy in pediatric cancers. Cancers. 2023;15(7):1963.
40. Lindsey ML, Lange RA, Parsons H, Andrews TC, Aune GJ. The tell-tale heart: molecular and cellular responses to childhood anthracycline exposure. AJP Heart Circ Physiol. 2014;307(10):H1379-H1389.
41. McNerney ME, Godley LA, Le Beau MM. Therapy-related myeloid neoplasms: when genetics and environment collide. Nat Rev Cancer. 2017;17(9):513-27.
42. Ikonomidou C. Chemotherapy and the pediatric brain. Mol Cell Pediatr. 2018;5(1):8.
43. Advani PG, Schonfeld SJ, Curtis RE, Dores GM, Linet MS, Sigel B, et al. Risk of therapy-related myelodysplastic syndrome/acute myeloid leukemia after childhood cancer: a population-based study. Leukemia. 2019;33(12):2947-78.
44. Vázquez-López R, Rojas OR, Moreno AI, Favila JEU, Barreto AP, G O, et al. Antibiotic-resistant septicemia in pediatric oncology patients associated with post-therapeutic neutropenic fever. Antibiotics. 2019;8(3):106.
45. de Lacerda AF, Martínez MA, Dumont B, Leiss U, Kokkinou G, Scheinemann K, et al. Embracing paediatric palliative care in paediatric oncology from diagnosis onwards. Pediatr Blood Cancer. 2023;70(10):e30593.
46. Soeteman M, Kappen TH, van Engelen M, Marcelis M, Kilsdonk E, van den Heuvel-Eibrink MM, et al. Validation of a modified bedside pediatric early warning system score for detection of clinical deterioration in hospitalized pediatric oncology patients: a prospective cohort study. Pediatr Blood Cancer. 2022;70(1):e29472.
47. Reschke A, Richards RM, Smith SM, Long AH, Marks LJ, Schultz L, et al. Development of clinical pathways to improve multidisciplinary care of high-risk pediatric oncology patients. Front Oncol. 2022;12:835742.
48. Bhosale SJ, Joshi M, Patil V, Kothekar AT, Myatra SN, Divatia JV, et al. Epidemiology and predictors of hospital outcomes of critically ill pediatric oncology patients: a retrospective study. Indian J Crit Care Med. 2022;25(10):1183-8.
49. Murphy Salem SL, Perez JM, Staffa SJ, Duncan CN, Graham RJ. Outcomes for pediatric oncology and hematopoietic stem cell transplantation patients who undergo tracheostomy placement: a Pediatric Health Information System database cohort study, 2009–2020. Pediatr Crit Care Med. 2024;25(6):e283-e290.
50. Llanos-Paez C, Staatz CE, Lawson R, Hennig S. A population pharmacokinetic model of gentamicin in pediatric oncology patients to facilitate personalized dosing. Antimicrob Agents Chemother. 2017;61(8):e00206-17.
51. Wraight TI, Namachivayam SP, Maiden MJ, Erickson S, Oberender F, Singh P, et al. Trends in childhood oncology admissions to ICUs in Australia and New Zealand. Pediatr Crit Care Med. 2023;24(10):e487-e497.
52. Ward E, DeSantis C, Robbins A, Kohler B, Jemal A. Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin. 2014;64(2):83-103.
53. Fujibuchi T, Matsubara K, Hamada N. NCRP statement No. 13 “NCRP recommendations for ending routine gonadal shielding during abdominal and pelvic radiography” and its accompanying documents. Underpinnings and recent developments. Hoken Butsuri. 2021;56(3):107-15.
54. Davis JT, Kwatra N, Schooler GR. Pediatric whole-body MRI: a review of current imaging techniques and clinical applications. J Magn Reson Imaging. 2014.
55. Davis JT, Kwatra N, Schooler GR. Pediatric whole-body MRI: a review of current imaging techniques and clinical applications. J Magn Reson Imaging. 2014;40(4):783-99.
56. Brenner DJ, Hall EJ. Computed tomography—an increasing source of radiation exposure. N Engl J Med. 2007;357(22):2277-84.
57. Pearce MS, Salotti JA, Little MP, McHugh K, Lee C, Kim KP, et al. Radiation exposure from CT scans in childhood and subsequent risk of leukaemia and brain tumours: a retrospective cohort study. Lancet. 2012;380(9840):499-505.
58. Frush DP, Applegate KE, Yan X, et al. Radiation exposure and dose reduction in pediatric imaging. Pediatr Radiol. 2003;33(4):226-34.
59. Strauss KJ, Goske MJ, Kaste SC, et al. Image gently: ten steps you can take to optimize image quality and lower CT dose for pediatric patients. AJR Am J Roentgenol. 2010;194(4):868-73.
60. Mettler FA Jr, Bhargavan M, Faulkner K, et al. Radiologic and nuclear medicine studies in the United States and worldwide: frequency, radiation dose, and comparison with other radiation sources—1950–2007. Radiology. 2009;253(2):520-31.
61. Thomsen HS. Contrast media safety—an update. Eur J Radiol. 2011;80(1):77-82.
62. Rabiner JE, Friedman LM, Khine H, Avner JR, Tsung JW. Accuracy of point-of-care ultrasound for diagnosis of skull fractures in children. Pediatrics. 2013;131(6):e1757-64.
63. Ferre RM, Sweeney K, Kahn J, et al. Ultrasound-guided lumbar puncture in pediatric oncology patients. Pediatr Emerg Care. 2017;33(2):96-100.
64. Sidhu PS, Cantisani V, Dietrich CF, et al. The evolving role of contrast-enhanced ultrasound in pediatric oncology. Ultraschall Med. 2018;39(6):602-15.
65. Prada F, Del Bene M, Fornaro R, et al. Intraoperative ultrasound in pediatric brain tumor surgery. Childs Nerv Syst. 2016;32(10):1911-20.
66. Brenner DJ, Elliston CD, Hall EJ, Berdon WE. Estimated risks of radiation-induced fatal cancer from pediatric CT. AJR Am J Roentgenol. 2001;176(2):289-96.
67. Slovis TL. Children, computed tomography radiation dose, and the as low as reasonably achievable (ALARA) concept. Pediatrics. 2003;112(4):971-2.
68. Kalra MK, Maher MM, Toth TL, et al. Strategies for CT radiation dose optimization. Radiology. 2004;230(3):619-28.
69. McCollough CH, Schueler BA. Calculation of effective dose. Med Phys. 2000;27(5):828-37.
70. Brenner DJ. Slowing the increase in the population dose resulting from CT scans. Radiat Res. 2010;174(6):809-15.
71. Dillman JR, Ellis JH, Cohan RH, Strouse PJ, Jan SC. Allergic-like breakthrough reactions to gadolinium contrast agents after corticosteroid and antihistamine premedication. AJR Am J Roentgenol. 2008;190(1):187-90.
72. Patel RA, Yee J. Pediatric contrast-induced nephropathy: what is the risk? Pediatr Radiol. 2013;43(1):1-7.
73. Clement O, Dewachter P, Mouton-Faivre C, et al. Immediate hypersensitivity to contrast agents: the French 5-year CIRTACI study. EClinicalMedicine. 2018;1:51-61.
74. Willemink MJ, Persson M, Pourmorteza A, et al. Photon-counting CT: technical principles and clinical prospects. Radiology. 2018;289(2):293-312.
75. Poretti A, Meoded A, Huisman TAGM. Neuroimaging of pediatric brain tumors: update on recent advances. Curr Opin Pediatr. 2012;24(6):697-703.
76. Messiou C, Orton M, Ang JE, et al. Advanced MRI for the assessment of treatment response in oncology. Br J Radiol. 2016;89(1062):20150314.
77. Chawla S, Wang S, Wolf RL, et al. Diffusion-weighted imaging in pediatric brain tumors. J Neurooncol. 2013;114(2):193-200.
78. Mafee MF, Goodwin J, Dorodi S. Orbital tumors and tumor-like lesions: role of CT and MRI. Radiol Clin North Am. 1999;37(1):169-83.
79. Hicks RJ, Lau EWF, Drummond E, et al. Role of PET in pediatric oncology. J Nucl Med. 2011;52(5):730-43.
80. Jadvar H. Targeted radionuclide therapy: an evolution toward precision oncology. AJR Am J Roentgenol. 2017;209(2):277-88.
81. Pirotte BJ, Lubansu A, Massager N, et al. Clinical impact of integrating positron emission tomography during surgery in pediatric brain tumors. J Neurosurg. 2010;113(3):533-43.
82. Dilsizian V, Bacharach SL, Beanlands RS, et al. PET myocardial perfusion and metabolism clinical imaging. J Nucl Cardiol. 2009;16(4):651.
83. Esposito C, Escolino M, Turrà F, et al. Robot-assisted surgery in pediatric oncology. World J Surg. 2017;41(4):835-42.
84. Warmann SW, Schaefer JF, Fuchs J. MRI-based 3D visualization in pediatric renal tumors. Eur J Pediatr Surg. 2014;24(3):212-8.
85. Abdelhafeez AH, Refaat M, Elsharkawy A. Fluorescence-guided surgery in pediatric oncology. J Pediatr Surg. 2018;53(11):2190-6.
86. Marescaux J, Diana M. Next step in minimally invasive surgery: computer-assisted surgery. Br J Surg. 2015;102(6):e90-9.
87. Sala F, Bricolo A, Talacchi A, et al. Intraoperative MRI in pediatric neurosurgery. Childs Nerv Syst. 2006;22(5):458-65.
88. Rothenberg SS. Thoracoscopic surgery in infants and children. Surg Endosc. 2008;22(2):329-35.
89. Parikh DH, Rasiah SV. Thoracoscopic surgery in pediatric oncology. Semin Pediatr Surg. 2007;16(4):256-62.
90. Stiller CA, Parkin DM. International variations in the incidence of childhood soft-tissue sarcomas. Paediatr Perinat Epidemiol. 1994;8(1):107-19.
91. Dupuis LL, Sung L, Molassiotis A, et al. 2016 updated MASCC/ESMO consensus recommendations. Support Care Cancer. 2017;25(1):333-40.
92. Sonis ST. Pathobiology of oral mucositis. J Support Oncol. 2004;2(1):21-32.
93. Stringer AM, Gibson RJ, Logan RM, et al. Chemotherapy-induced mucositis: the role of the gastrointestinal microbiome. Cancer Treat Rev. 2009;35(8):697-706.
94. Cheng KKF, Lee V, Li CH, et al. Incidence and risk factors of oral mucositis in pediatric oncology patients. Support Care Cancer. 2011;19(5):751-9.
95. Elting LS, Keefe DM, Sonis ST, et al. Burden of illness of chemotherapy-induced oral mucositis. Cancer. 2008;113(10):2704-13.
96. Gupta S, Howard SC, Hunger SP, et al. Treating childhood cancer in low- and middle-income countries. Nat Rev Cancer. 2015;15(11):673-82.
97. Landier W, Bhatia S, Eshelman DA, et al. Adherence to chemotherapy administration guidelines. J Clin Oncol. 2004;22(21):4359-67.
98. Rinke ML, Bundy DG, Shore AD, et al. Pediatric chemotherapy safety and quality improvement. Pediatrics. 2012;130(6):e1464-70.
99. Delaney G, Jacob S, Featherstone C, Barton M. The role of radiotherapy in cancer treatment. Cancer. 2005;104(6):1129-37.
100. Merchant TE, Pollack IF, Loeffler JS. Brain tumors across the age spectrum. J Clin Oncol. 2010;28(32):4787-96.
101. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354(2):166-78.
102. Yock TI, Tarbell NJ. Technology insight: proton beam radiotherapy. Nat Clin Pract Oncol. 2004;1(2):97-103.
103. Eaton BR, Yock T, Merchant TE. Advances in radiotherapy for pediatric cancer. Lancet Oncol. 2015;16(19):e460-70.
104. Duffton A, McNee SG, Coles CE, et al. Pediatric radiotherapy facilities and emergency preparedness. Clin Oncol. 2012;24(4):e57-64.
105. Lutz S, Chow E, Hoskin P, et al. Palliative radiotherapy. Radiother Oncol. 2014;110(3):479-85.
106. Constine LS, Ronckers CM, Hua CH, et al. Pediatric radiation oncology training. Int J Radiat Oncol Biol Phys. 2008;72(3):695-700.
107. Atun R, Jaffray DA, Barton MB, et al. Expanding global access to radiotherapy. Lancet Oncol. 2015;16(10):1153-86.
108. Mody R, Prensner JR, Everett J, et al. Precision medicine in pediatric oncology. Cancer Discov. 2017;7(5):446-59.
109. Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015;372(9):793-5.
110. Parsons DW, Roy A, Yang Y, et al. Diagnostic yield of clinical tumor and germline whole-exome sequencing. JAMA Oncol. 2016;2(5):616-24.
111. Mossé YP, Laetsch TW, Nagasubramanian R, et al. Efficacy of larotrectinib in TRK fusion–positive cancers. N Engl J Med. 2018;378(8):731-9.
112. Pearson ADJ, Pfister SM, Baruchel A, et al. From biology to clinical trials. Lancet Oncol. 2016;17(10):e415-25.
113. Allen CE, Laetsch TW, Mody R, et al. Targeted therapy in pediatric oncology. Nat Rev Clin Oncol. 2017;14(5):277-88.
114. Hargrave DR, Bouffet E, Tabori U, et al. Pediatric brain tumors. Nat Rev Dis Primers. 2019;5(1):1-25.
115. Vassal G, Kearns P, Blanc P, et al. New drugs for children and adolescents with cancer. Lancet Oncol. 2013;14(2):e60-9.
116. Yu AL, Gilman AL, Ozkaynak MF, et al. Anti-GD2 antibody with GM-CSF and interleukin-2. N Engl J Med. 2010;363(14):1324-34.
117. Cheung NK, Dyer MA. Neuroblastoma. N Engl J Med. 2013;369(21):2021-30.
118. Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults. N Engl J Med. 2018;378(5):439-48.
119. Mackall CL, Rhee EH, Read EJ, et al. A pilot study of consolidative immunotherapy. Clin Cancer Res. 2008;14(15):4850-8.
120. Majzner RG, Mackall CL. CAR T cell therapy in solid tumors. Cancer Discov. 2018;8(10):1219-26.
121. Lehrnbecher T, Robinson P, Fisher B, et al. Guideline for fever and neutropenia. J Clin Oncol. 2012;30(35):4427-38.
122. Lehrnbecher T, Cornely OA, Bow EJ, et al. Isavuconazole for pediatric patients. Clin Infect Dis. 2016;63(11):1529-36.
123. Fisher BT, Zaoutis TE, Dvorak CC, et al. Pediatric invasive fungal infection risk score. Clin Infect Dis. 2014;59(9):1224-31.
124. Gerding DN, Johnson S, Rupnik M, et al. Clostridioides difficile infection. Clin Infect Dis. 2014;59(2):e1-38.
125. Pieters R, Schrappe M, De Lorenzo P, et al. A treatment protocol for infants with ALL. Blood. 2007;109(3):926-35.
126. Alexander S, Fisher BT, Gaur AH, et al. Effect of levofloxacin prophylaxis. JAMA. 2018;320(10):995-1004.
127. Oeffinger KC, Hudson MM. Long-term complications following childhood cancer. Annu Rev Med. 2004;55:349-67.
128. Lipshultz SE, Franco VI, Miller TL, et al. Cardiovascular disease in adult survivors of childhood cancer. Annu Rev Med. 2015;66:161-76.
129. Travis LB, Hill DA, Dores GM, et al. Breast cancer following radiotherapy. J Natl Cancer Inst. 2005;97(19):1428-37.
130. Gurney JG, Ness KK, Sibley SD, et al. Metabolic syndrome and cardiovascular risk. J Clin Oncol. 2006;24(31):4799-806.
131. Armstrong GT, Oeffinger KC, Chen Y, et al. Modifiable risk factors and major cardiac events. J Clin Oncol. 2013;31(29):3673-80.
132. Pritchard-Jones K, Dixon-Woods M, Naafs-Wilstra M, et al. Improving access to clinical trials for children. Lancet. 2011;378(9801):1593-601.
133. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-74.
134. Vassal G, Fitzgerald E, Schrappe M, et al. Challenges for drug development for children. Nat Rev Clin Oncol. 2013;10(12):712-23.
Article Sidebar
Published
Jan 9, 2026
Article Details
How to Cite
1.
The future of pediatric oncology: Comprehensive review of causes, mortality, and treatment strategies. Pharm Pract (Granada) [Internet]. 2026 Jan. 9 [cited 2026 Jan. 25];23(4):1-15. Available from: https://www.pharmacypractice.org/index.php/pp/article/view/3215
Section
Review
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
How to Cite
1.
The future of pediatric oncology: Comprehensive review of causes, mortality, and treatment strategies. Pharm Pract (Granada) [Internet]. 2026 Jan. 9 [cited 2026 Jan. 25];23(4):1-15. Available from: https://www.pharmacypractice.org/index.php/pp/article/view/3215